[{"id":"1ec7ade3-a1ff-44d4-b7ca-e3d08c57d7b8","acronym":"IM-TMI","url":"https://clinicaltrials.gov/study/NCT04187105","created_at":"2021-01-18T20:24:37.787Z","updated_at":"2024-07-02T16:35:37.511Z","phase":"Phase 2","brief_title":"BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)","source_id_and_acronym":"NCT04187105 - IM-TMI","lead_sponsor":"University of Illinois at Chicago","biomarkers":" RUNX1 • ASXL1 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":" | ","alterations":" RUNX1 mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • Chr t(9;11)","tags":["RUNX1 • ASXL1 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation • ASXL1 mutation • MLL rearrangement • MLL rearrangement • MLL translocation • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 01/27/2020","start_date":" 01/27/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-09-11"}]